Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Biol. Res ; 50: 19, 2017. graf
Article in English | LILACS | ID: biblio-950871

ABSTRACT

BACKGROUND: Bromodomain-containing protein 4 (BRD4) inhibition is a new therapeutic strategy for many malignancies. In this study, we aimed to explore the effect of BRD4 inhibition by JQ1 on in vitro cell growth, migration and invasion of salivary adenoid cystic carcinoma (SACC). METHODS: The human normal epithelial cells and SACC cells (ACC-LM and ACC-83) were treated with JQ1 at concentrations of 0, 0.1, 0.5 or 1 µM. Cell Counting Kit-8 (CCK-8) assay was performed to evaluate cell proliferation. Cell apoptosis and cell cycle distribution was evaluated by Flow cytometry. Immunofluorescence staining was used to examine the expression of BRD4 in SACC cells. The quantitative real-time polymerase chain reaction (qRT-PCR) assay and western blot assay were performed to examine messenger RNA (mRNA) and protein levels in SACC cells. Wound- healing assay and transwell assay were used to evaluate the activities of migration and invasion of SACC cells. RESULTS: JQ1 exhibits no adverse effects on proliferation, cell cycle and cell apoptosis of the normal human epithelial cells, while suppressed proliferation and cell cycle, and induced apoptosis of SACC cells, down-regulated the mRNA and protein levels of BRD4 in SACC cells, meanwhile reduced protein expressions of c-myc and BCL-2, two known target genes of BRD4. Moreover, JQ1 inhibited SACC cell migration and invasion by regulating key epithelial-mesenchymal transition (EMT) characteristics including E-cadherin, Vimentin and Twist. CONCLUSIONS: BRD4 is an important transcription factor in SACC and BRD4 inhibition by JQ1 may be a new strategy for SACC treatment.


Subject(s)
Humans , Azepines/pharmacology , Transcription Factors/antagonists & inhibitors , Triazoles/pharmacology , Salivary Gland Neoplasms/drug therapy , Nuclear Proteins/antagonists & inhibitors , Cell Movement/drug effects , Carcinoma, Adenoid Cystic/drug therapy , Cell Proliferation/drug effects , Neoplasm Invasiveness/pathology , Salivary Gland Neoplasms/pathology , Down-Regulation , Carcinoma, Adenoid Cystic/pathology , Cell Cycle Proteins , Cell Line, Tumor , Real-Time Polymerase Chain Reaction
2.
Journal of Korean Medical Science ; : 987-992, 2012.
Article in English | WPRIM | ID: wpr-154194

ABSTRACT

Inflammation is closely related to the progression of cancer as well as tumorigenesis. Here, we investigated the effect of prostaglandin E2 (PGE2) and interleukin-1beta (IL-1beta) on E-cadherin expression in SNU719 gastric cancer cells. E-cadherin expression decreased as the dose or exposure time of PGE2 and IL-1beta increased, whereas Snail expression increased with dose or time of PGE2 and IL-1beta. E-cadherin expression reduced by PGE2 treatment increased after the transfection of Snail siRNA. Neutralization of IL-1beta using anti-IL-1beta antibody blocked the expression pattern of E-cadherin and Snail occurred by IL-1beta treatment. However, there was no synergic effect of IL-1beta and PGE2 on the expression pattern of E-cadherin and Snail. In conclusion, inflammatory mediators reduced E-cadherin expression by enhancing Snail expression in gastric cancer cells. Inflammation-induced transcriptional regulation of E-cadherin in gastric cancer has implications for targeted chemoprevention and therapy.


Subject(s)
Humans , Antibodies/immunology , Antineoplastic Agents/pharmacology , Cadherins/metabolism , Cell Line, Tumor , Dinoprostone/pharmacology , Gene Expression Regulation/drug effects , Interleukin-1beta/immunology , RNA Interference , RNA, Small Interfering/metabolism , Stomach Neoplasms/metabolism , Transcription Factors/antagonists & inhibitors
3.
Experimental & Molecular Medicine ; : 428-436, 2010.
Article in English | WPRIM | ID: wpr-27760

ABSTRACT

Inadequate apoptosis contributes to synovial hyperplasia in rheumatoid arthritis (RA). Recent study shows that low expression of Puma might be partially responsible for the decreased apoptosis of fibroblast-like synoviocytes (FLS). Slug, a highly conserved zinc finger transcriptional repressor, is known to antagonize apoptosis of hematopoietic progenitor cells by repressing Puma transactivation. In this study, we examined the expression and function of Slug in RA FLS. Slug mRNA expression was measured in the synovial tissue (ST) and FLS obtained from RA and osteoarthritis patients. Slug and Puma mRNA expression in FLS by apoptotic stimuli were measured by real-time PCR analysis. FLS were transfected with control siRNA or Slug siRNA. Apoptosis was quantified by trypan blue exclusion, DNA fragmentation and caspase-3 assay. RA ST expressed higher level of Slug mRNA compared with osteoarthritis ST. Slug was significantly induced by hydrogen peroxide (H2O2) but not by exogenous p53 in RA FLS. Puma induction by H2O2 stimulation was significantly higher in Slug siRNA-transfected FLS compared with control siRNA-transfected FLS. After H2O2 stimulation, viable cell number was significantly lower in Slug siRNA-transfected FLS compared with control siRNA-transfected FLS. Apoptosis enhancing effect of Slug siRNA was further confirmed by ELISA that detects cytoplasmic histone-associated DNA fragments and caspase-3 assay. These data demonstrate that Slug is overexpressed in RA ST and that suppression of Slug gene facilitates apoptosis of FLS by increasing Puma transactivation. Slug may therefore represent a potential therapeutic target in RA.


Subject(s)
Humans , Apoptosis/drug effects , Apoptosis Regulatory Proteins/genetics , Arthritis, Rheumatoid/genetics , Cells, Cultured , Drug Evaluation, Preclinical , Fibroblasts/drug effects , Hydrogen Peroxide/pharmacology , Proto-Oncogene Proteins/genetics , RNA, Small Interfering/pharmacology , Synovial Membrane/cytology , Transcription Factors/antagonists & inhibitors , Transcriptional Activation/drug effects , Transfection
4.
Indian J Biochem Biophys ; 2009 Dec; 46(6): 447-460
Article in English | IMSEAR | ID: sea-135228

ABSTRACT

Current therapeutic approaches for the treatment of asthma have limitations in their ability to target all the features of the disease. Indeed, existing pharmacological asthma therapies are based on decades old strategies that were developed prior to the rapid growth in knowledge stemming from cell and molecular biology in the past decade. Thus, there is an unmet need for developing new drugs to target these features along with improved efficacy and safety. In the present review, the limitations of prevalent pharmacological asthma therapy are discussed briefly, and some explanations are suggested as to why new therapeutic targets are required to treat asthma, and finally directions for novel asthma therapies are proposed.


Subject(s)
Animals , Asthma/drug therapy , Asthma/enzymology , Asthma/genetics , Asthma/metabolism , Bronchodilator Agents/metabolism , Bronchodilator Agents/pharmacology , Bronchodilator Agents/therapeutic use , Cytokines/metabolism , Enzyme Inhibitors/metabolism , Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/therapeutic use , Humans , Oligonucleotides/metabolism , Oligonucleotides/therapeutic use , Transcription Factors/antagonists & inhibitors
5.
J Biosci ; 2007 Sep; 32(6): 1133-8
Article in English | IMSEAR | ID: sea-110932

ABSTRACT

Beta-catenin is the key transducer of Wingless-type MMTV integration site family member (Wnt) signalling, upregulation of which is the cause of cancer of the colon and other tissues. In the absence of Wnt signals, beta-catenin is targeted to ubiquitin-proteasome-mediated degradation. Here we present the functional characterization of E3-ubiquitin ligase encoded by cul4B. RNAi-mediated knock-down of Cul4B in a mouse cell line C3H T10 (1/2) results in an increase in beta-catenin levels. Loss-of-function mutation in Drosophila cul4 also shows increased beta-catenin/Armadillo levels in developing embryos and displays a characteristic naked-cuticle phenotype. Immunoprecipitation experiments suggest that Cul4B and beta-catenin are part of a signal complex in Drosophila, mouse and human. These preliminary results suggest a conserved role for Cul4B in the regulation of beta-catenin levels.


Subject(s)
Animals , Animals, Genetically Modified , Armadillo Domain Proteins/antagonists & inhibitors , Cell Line, Tumor , Cullin Proteins/genetics , Down-Regulation/genetics , Drosophila Proteins/antagonists & inhibitors , Drosophila melanogaster/genetics , Humans , Larva/genetics , Mice , Mice, Inbred C3H , Transcription Factors/antagonists & inhibitors , Ubiquitin-Protein Ligases/physiology , beta Catenin/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL